Cellular probing using phytoceuticals encapsulated advanced delivery systems in ameliorating lung diseases: Current trends and future prospects

• Published in: International immunopharmacology 2024-11, Vol.141, p.112913, Article 112913
• Main Authors: Datsyuk, Jessica Katrine, De Rubis, Gabriele, Paudel, Keshav Raj, Kokkinis, Sofia, Oliver, Brian Gregory George, Dua, Kamal
• Format: Article
• Language: English
• Subjects: Advanced drug delivery systems; Animals; Anti-Inflammatory Agents - administration & dosage; Anti-Inflammatory Agents - therapeutic use; Asthma; COPD; Drug Delivery Systems; Humans; Lung Diseases - drug therapy; Phytoceuticals; Phytochemicals - administration & dosage; Phytochemicals - therapeutic use; Pulmonary Disease, Chronic Obstructive - drug therapy
• ISSN: 1567-5769; 1878-1705; 1878-1705
• DOI: 10.1016/j.intimp.2024.112913

•Respiratory diseases like COPD and Asthma continue to pose a significant global medical challenge.•The implementation of high-specificity cellular probing has the ability to manage pathogenesis of lung disease.•Advanced drug delivery enhances the pharmacokinetic characteristics of phytoceuticals, improving therapeutic outcomes. Chronic respiratory diseases such as Chronic Obstructive Pulmonary Disease (COPD) and asthma have posed a significant healthcare and economic cost over a prolonged duration worldwide. At present, available treatments are limited to a range of preventive medicines, such as mono- or multiple-drug therapy, which necessitates daily use and are not considered as viable treatments to reverse the inflammatory processes of airway remodelling which is inclusive of the alteration of intra and extracellular matrix of the airway tract, death of epithelial cells, the increase in smooth muscle cell and the activation of fibroblasts. Hence, with the problem in mind a considerable body of study has been dedicated to comprehending the underlying factors that contribute to inflammation within the framework of these disorders. Hence, adequate literature that has unveiled the necessary cellular probing to reduce inflammation in the respiratory tract by improving the selectivity and precision of a novel treatment. However, through cellular probing cellular mechanisms such as the downregulation of various markers, interleukin 8, (IL-8), Interleukin 6 (IL-6), interleukin 1β (IL-1β) and tumor necrosis factor-α (TNF-α) have been uncovered. Hence, to target such cellular probes implementation of phytoceuticals encapsulated in an advanced drug delivery system has shown potential to be a solution with in vitro and in vivo studies highlighting their anti-inflammatory and antioxidant effects. However, the high costs associated with advanced drug delivery systems and the limited literature focused exclusively on nanoparticles pose significant challenges. Additionally, the biochemical characteristics of phytoceuticals due to poor solubility, limited bioavailability, and difficulties in mass production makes it difficult to implement this product as a treatment for COPD and asthma. This study aims to examine the integration of many critical features in the context of their application for the treatment of chronic inflammation in respiratory disorders.